...
首页> 外文期刊>Journal of Medicinal Chemistry >Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts
【24h】

Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts

机译:雷公藤甲素的膦酰氧甲基前药:人结肠腺癌和卵巢癌异种移植物的合成,物理化学表征和功效。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

A disodium phosphonooxymethyl prodrug of the antitumor agent triptolide was prepared from the natural product in three steps (39% yield) and displayed excellent aqueous solubility at pH 7.4 (61 mg/mL) compared to the natural product (17 mu g/mL). The estimated shelf life (t(90)) for hydrolysis of the prodrug at 4 degrees C and pH 7.4 was found to be two years. In a mouse model of human colon adenocarcinoma (HT-29), the prodrug administered intraperitoneally was effective in reducing or eliminating xenograft tumors at dose levels as low as 0.3 mg/kg when given daily and at 0.9 mg/kg when given less frequently. When given via intraperitoneal and oral routes at daily doses of 0.6 and 0.9 mg/kg, the pro drug was also effective and well tolerated in a mouse model of human ovarian cancer (A2780).
机译:从天然产物中分三步制备抗肿瘤剂雷公藤内酯的膦酰氧甲基甲基二钠前药(收率39%),与天然产物(17μg / mL)相比,在pH 7.4(61 mg / mL)下显示出优异的水溶性。发现在4摄氏度和pH 7.4下水解前药的估计保质期(t(90))为两年。在人结肠腺癌(HT-29)小鼠模型中,腹膜内给药的前药可有效减少或消除异种移植肿瘤,每日给药剂量低至0.3 mg / kg,不频繁给药剂量低至0.9 mg / kg。当通过腹膜内和口服途径以0.6和0.9 mg / kg的日剂量给药时,该原药在人卵巢癌的小鼠模型(A2780)中也有效且耐受良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号